Theme #1: Triple-negative breast cancer: Improving outcomes
Variation 1: How chemosensitive is triple-negative (basal-like) breast cancer?

Ian Smith, MD
Royal Marsden Hospital
London, United Kingdom

Theme #1: Triple-negative breast cancer: Improving outcomes
Variation 2: Incorporating targeted agents: When and in what sequence

Lisa Carey, MD
University of North Carolina
Chapel Hill, North Carolina, United States
Additional comments by José Baselga, MD

Theme #2: Adjuvant systemic therapy for postmenopausal endocrine-responsive breast cancer: Multiple variations on a central theme
Variation 1: Risk assessment and the role of gene expression profiles in treatment planning

Terry Mamounas, MD
Northeastern Ohio Universities
Canton, Ohio, United States

Theme #2: Adjuvant systemic therapy for postmenopausal endocrine-responsive breast cancer: Multiple variations on a central theme
Variation 2: Systemic adjuvant therapy: What's the best approach?

Stephen Jones, MD
US Oncology Research
Dallas, Texas, United States

Theme #2: Adjuvant systemic therapy for postmenopausal endocrine-responsive breast cancer: Multiple variations on a central theme
Variation 3: Addressing concerns regarding bone health

Robert Coleman, MD
Weston Park Hospital
Sheffield, United Kingdom

Theme #3: Metastatic HER2-amplified breast cancer: Therapeutic options
Variation 1: Disease progression following adjuvant trastuzumab: What's next?

Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, Italy

Theme #3: Metastatic HER2-amplified breast cancer: Therapeutic options
Variation 2: What if progression occurs during trastuzumab?

José Baselga, MD
Hospital Vall d'Hebron
Barcelona, Spain